SNY vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about Sanofi (SNY) and Novo Nordisk A/S (NVO).

Performance

SNY vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sanofi (SNY) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

SNY vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SNY Sanofi	-1.51%	4.93%	1.09%	6.55%	0.57%	7.00%	0.39%	20.47%	6.06%	9.96%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Fundamentals

Market Cap SNY : $116.50B NVO : $162.26B
EPS SNY : $3.18 NVO : $22.15
PE Ratio SNY : 15.02 NVO : 1.65
PS Ratio SNY : 2.51 NVO : 0.55
PB Ratio SNY : 1.63 NVO : 0.84
Total Revenue (TTM) SNY : $46.72B NVO : $297.20B
Gross Profit (TTM) SNY : $33.79B NVO : $240.66B
EBITDA (TTM) SNY : $12.68B NVO : $153.18B

Returns By Period

In the year-to-date period, SNY achieves a -1.51% return, which is significantly higher than NVO's -25.80% return. Over the past 10 years, SNY has outperformed NVO with an annualized return of 5.86%, while NVO has yielded a comparatively lower 5.04% annualized return.

SNY

• 1D: -0.93%
• 1M: 0.15%
• YTD: -1.51%
• 6M: -4.08%
• 1Y: -8.27%
• 3Y*: -0.31%
• 5Y*: 3.35%
• 10Y*: 5.86%

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

SNY vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNY

SNY Risk / Return Rank: 23
SNY Sharpe Ratio Rank: 27
SNY Sortino Ratio Rank: 24
SNY Omega Ratio Rank: 24
SNY Calmar Ratio Rank: 22
SNY Martin Ratio Rank: 20

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNY vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SNY	NVO	Difference
Sharpe ratio Return per unit of total volatility	-0.30	-0.81	+0.51
Sortino ratio Return per unit of downside risk	-0.23	-0.99	+0.76
Omega ratio Gain probability vs. loss probability	0.97	0.86	+0.11
Calmar ratio Return relative to maximum drawdown	-0.57	-0.82	+0.25
Martin ratio Return relative to average drawdown	-1.12	-1.41	+0.30
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SNY vs. NVO - Sharpe Ratio Comparison

The current SNY Sharpe Ratio is -0.30, which is higher than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of SNY and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	SNY	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.30	-0.81	+0.51
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.14	0.10	+0.04
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.25	0.16	+0.09
Sharpe Ratio (All Time) Calculated using the full available price history	0.21	0.46	-0.25

Correlation

The correlation between SNY and NVO is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

SNY vs. NVO - Dividend Comparison

SNY's dividend yield for the trailing twelve months is around 4.63%, less than NVO's 4.94% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
SNY Sanofi	4.63%	4.56%	4.22%	3.83%	4.32%	3.80%	3.61%	3.47%	4.29%	3.82%	4.11%	3.77%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

SNY vs. NVO - Drawdown Comparison

The maximum SNY drawdown since its inception was -46.46%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for SNY and NVO.

Drawdown Indicators

	SNY	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-46.46%	-74.70%	+28.24%
Max Drawdown (1Y) Largest decline over 1 year	-17.87%	-55.03%	+37.16%
Max Drawdown (5Y) Largest decline over 5 years	-33.52%	-74.70%	+41.18%
Max Drawdown (10Y) Largest decline over 10 years	-33.52%	-74.70%	+41.18%
Current Drawdown Current decline from peak	-16.11%	-73.49%	+57.38%
Average Drawdown Average peak-to-trough decline	-12.15%	-17.56%	+5.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.06%	31.83%	-22.77%

Volatility

SNY vs. NVO - Volatility Comparison

The current volatility for Sanofi (SNY) is 6.79%, while Novo Nordisk A/S (NVO) has a volatility of 9.39%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SNY	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.79%	9.39%	-2.60%
Volatility (6M) Calculated over the trailing 6-month period	16.85%	38.79%	-21.94%
Volatility (1Y) Calculated over the trailing 1-year period	27.50%	54.16%	-26.66%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.65%	37.82%	-13.17%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.51%	32.28%	-8.77%

Financials

SNY vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Sanofi and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Sanofi reported a gross profit of 8.58B and revenue of 12.21B. Therefore, the gross margin over that period was 70.3%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Sanofi reported an operating income of -1.04B and revenue of 12.21B, resulting in an operating margin of -8.5%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Sanofi reported a net income of -801.00M and revenue of 12.21B, resulting in a net margin of -6.6%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.